Home Tests Sentis™ Pan-Cancer Companion Diagnostic (ctDNA)

Sentis™ Pan-Cancer Companion Diagnostic (ctDNA)

Umm Al Hamam Al Gharbi, Riyadh - 145KM

The Sentis™ Pan‑Cancer Companion Diagnostic (ctDNA) is a state-of-the-art, minimally invasive liquid biopsy test developed by BGI. It detects tumor-derived DNA (ctDNA) from a simple blood sample, offering real-time genomic insights across a broad range of solid tumors. Using highly sensitive next-generation sequencing (NGS), the assay identifies key alterations—such as SNVs, insertions/deletions (InDels), CNVs, and gene fusions—that inform tailored treatment strategies including targeted therapies and immunotherapy 

Why Choose Sentis™ Pan-Cancer (ctDNA)?
1-Broad Genomic Coverage: Screens hundreds of cancer-related genes and common alterations, enabling comprehensive mutation profiling.
2- Non-Invasive & Dynamic: Provides a less invasive alternative to tissue biopsy with the ability to monitor tumor evolution and treatment response in real time .
3- High Sensitivity: Achieves deep sequencing depth (up to 3000× for ctDNA), enhancing detection of low-abundance variants

Disclaimer: You must consult your physician.
Test results should always be interpreted in consultation with your treating physician.
At Genalive, we provide certified genetic counselors who can assist in collecting detailed family history and help identify the most appropriate genetic test for each patient.